03 Profile
Vital Signsby Bridgehead
Hansard to 12 November 2026 · 31,484 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Academic · Heart disease & stroke
Paul Burton: no photograph is held, so the academic plate is shown instead.
Academic
Paul Burton
M.D., Ph.D., chief medical officer at Amgen
June 2026July 2026Aug 2026Sept 2026Oct 2026Nov 2026to date
1
Quoted in the press, across 1 topic since 8 Jun 2026
02 Quoted on · 1 of 29 topics
Paul Burton: key facts
- Kind of voice
- Academic
- Role
- M.D., Ph.D., chief medical officer at Amgen
- Quoted on
- Heart disease & stroke
- Press coverage
- Quoted in the press
- Most recently quoted
- 3 Sept 2026
- First quoted
- 8 Jun 2026
04 On the record · press
What Paul Burton has said
By outlet · bar length shows relative volume
- fiercepharma.com
Where Paul Burton has been quoted
- ESC: Amgen CMO flags Repatha 'inflection' amid new data on mortality benefitfiercepharma.com · 3 Sept 2026
- ADA: Amgen highlights Repatha perks, GLP-1 pitfalls in push to boost cardiometabolic pedigreefiercepharma.com · 8 Jun 2026
How we found the articles that name Paul Burton: we searched news for these terms.
- heart disease
- cardiovascular
- stroke
- cardiac
- heart attack
- stroke rehabilitation
Also searched with “heart disease” in each of 8 national papers, and in the Guardian by editor tag, and in trade press by category. Every term for Heart disease & stroke
Verbatim
“I think when you take all of that together, it says in the real world there needs to be more urgency -- more focus on getting patients' LDL-C lower.”
“[E]arlier intensive lipid-lowering therapy with Repatha in these patients with high-risk diabetes, but without a cardiovascular event, profoundly protects them”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
- Heart Charity Calls for National Strategy to Prevent Sudden DeathsCharity Today News
- Stroke treatment callsDnG24
- Stopping GLP-1s linked to twice the risk of heart attack, stroke or death in type 2 diabetesThe Pharmaceutical Journal
Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 13 Nov 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.